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0929-6646/Copyright ª 2015, ElsevierBackground/Purpose: Microglia have a crucial role in maintaining neuronal homeostasis in the
central nervous system. Immune factors released from microglia have important roles in noci-
ceptive signal transduction. Activation of microglia seems to be a shared mechanism in path-
ological pain and morphine tolerance because pharmacological attenuation of microglia
activation provides satisfactory management in both situations.
Methods: In the present study, we investigated the effect of 1nM (þ)-naloxone, which is not an
opioid receptor antagonist, on morphine-induced activation of microglia EOC13.31 cells.
Results: Our results showed that 1mM morphine enhanced microglia activation and migration,
decreased a-tubulin acetylation, and induced heat shock protein 90 (HSP90) fragmentation and
histone deacetylase 6 (HDAC6) expression. Morphine-induced a-tubulin deacetylation and
HSP90 fragmentation were HDAC6-dependent. Pretreatment with (þ)-naloxone (1nM) inhib-
ited morphine-evoked microglia activation and chemotaxis and prevented a-tubulin deacety-
lation and HSP90 fragmentation by inhibiting HDAC6 expression.
Conclusion: Based on the findings of the present study, we suggest that (þ)-naloxone inhibits
morphine-induced microglia activation by regulating HDAC6-dependent a-tubulin deacetyla-
tion and HSP90 fragmentation.
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Ultralow dose of (þ)-naloxone and microglia 447Introduction
The clinical use of opioids, which are fundamental in the
treatment of pain, is limited by their adverse effects such as
tolerance and hyperalgesia. To explore new pain therapies,
it is necessary to have a clear understanding of the devel-
opment of opioid tolerance and neuropathic pain, which
share the same feature of diminished morphine analgesia.1
We previously reported that ()-ultralow dose naloxone
inhibits spinal microglia reactivity and thus attenuates
morphine tolerance.2 We and others have shown it also in-
hibits neuropathic pain.3,4 A recent study demonstrated that
the glia-modulating agents minocycline and propentofylline
attenuate the development of morphine tolerance by
inhibiting rat spinal microglia reactivity.5 These results
suggest the involvement of microglia activation in the
development of morphine tolerance and/or hyperalgesia.
Under normal conditions,microglia have a small soma that
bears thin-branched processes.6 In the injured central ner-
vous system, ramified microglia rapidly transform from a
resting state to an active state, release a variety of cytokines,
proliferate,migrate, and becomephagocytic.7 Lamellipodia,
filopodia, and membrane ruffles are essential for cell
migration and phagocytosis,8 and membrane protrusion is
dependent on cytoskeletal rearrangement such as the for-
mation of lamellar networks, polymerization of actin fila-
ments, and tubulin assembly.9 Recent studies have suggested
that microglia activation during neuropathy leads to
abnormal pain signal processing10; however, the mechanism
is poorly understood. We have previously demonstrated that
chronic morphine treatment enhances microglia reactivity,
which induces the release of proinflammatory cytokines and
directly affect the interaction between microglia and noci-
ceptive neurons,11 and that ultralow dose ()-naloxone
(15 pg) cotreatment with morphine inhibits microglia acti-
vation and reverses antinociceptive effect of morphine in
morphine-tolerant rats.12,13 These results suggest that ul-
tralow dose ()-naloxone may be clinically valuable in pain
management. Microglia constitute only 5e12% of all cells in
the central nervous system (CNS), which leads to some
important role ofmicroglia been ignored. In addition, chronic
morphine treatment changes opioid receptor conformation
and sensitization, and decreases available receptors. It is
unclear whether ultralow dose ()-naloxone suppresses
neuroinflammation via opioid receptors or by other signal
pathways. The aim of the present study was therefore to
examine the pathways affected by ultralow dose
(þ)-naloxone, which does not act through opioid re-
ceptors.14,15 We found that it does not inhibit microglia
activation by acting on opioid receptors. It instead down-
regulates the histone deacetylase 6 (HDAC6)-dependent a-
tubulin deacetylation signaling pathway.
Methods
Cell culture
EOC13.31 mouse microglia cells (CRL-2468; American Type
Culture Collection; Bioresource Collection and Research
Center, Food Industry Research and Development Institute,
Hsinchu, Taiwan) were grown in 70% Dulbecco’s modifiedEagle’s medium (DMEM) containing 4.5 g/L glucose, 10%
fetal bovine serum (FBS), and 20% conditioned medium
from cultures of the LADMAC cell line (American Type
Culture Collection; Bioresource Collection and Research
Center).16 The medium was changed every 3e4 days. Cells
were collected and used immediately for chemotaxis ex-
periments or were plated for Western blot analysis or
immunocytochemistry.
Drug delivery for culture cells
Before the experiment, the cells were washed three times
with serum-free DMEM, starved for 4 hours in the same
medium, and incubated for 30 minutes with the medium
and 1nM (þ)-naloxone (a generous gift from Dr. Jau-Shyong
Hong, National Institutes of Health, Research Triangle Park,
NC, USA) or 1nM tubacin (SigmaeAldrich, St. Louis, MO,
USA). The medium or 1mM morphine (SigmaeAldrich) was
then added. Incubation continued for 2 hours. The cells
were thereafter gently harvested in phosphate-buffered
saline (PBS)/1mM EDTA and were used for migration,
Western blotting, or immunocytochemical studies.
Chemotaxis assay
Before the chemotaxis assay, the cells were washed three
times with serum-free DMEM, starved for 4 hours in the
same medium, and then gently harvested in PBS/1mM
EDTA, and counted. They were resuspended in serum-free
medium at 1  104 cells per 100 mL, and placed in silicon-
ized low-adhesion microcentrifuge tubes for drug treat-
ment. They were then incubated for 30 minutes in serum-
free DMEM with or without 1nM (þ)-naloxone. The me-
dium or 1mM morphine was then added and incubation
continued for 2 hours. The cells were counted using Trypan
blue to estimate survival (>99% viability). The treated cells
were added (1  103 cells in 50 mL) to the upper wells of a
48-well microchemotaxis Boyden chamber (Neuro Probe;
Cabin John, MD, USA). The lower wells were filled with
DMEM containing 10% FBS. The chambers were then incu-
bated for 1 hour in a humidified incubator at 37C in 5%
carbon dioxide (CO2). After removing any cells remaining on
top of the membrane, the number of EOC13.31 cells that
had migrated to the underside of the filter (25 mm  80 mm
polycarbonate membrane, 3.0-mm pore size; Osmonics,
Livermore, CA, USA) was examined. The membrane was
rinsed with PBS and the migrated cells were fixed with
methanol and stained with crystal violet (Sigma-Aldrich).
The membrane was then rinsed twice with distilled water,
dried, inverted, and mounted on a microscope slide for
analysis. Images of six random fields for each well were
captured using an Olympus BX 50 fluorescence microscope
(Olympus, Optical, Tokyo, Japan; 20 objective). The cells
were counted by averaging the results for all six fields. All
experiments were performed at least three times with
n Z 18 per trial.
Western blotting
EOC13.31 cells at a density of 5  105 cells/cm2 were plated
on poly-L-lysine-coated culture dishes (Nunc, Roskilde,
448 R.-Y. Tsai et al.Denmark); washed three times with serum-free DMEM;
starved for 4 hours in the same medium; and then incu-
bated for 30 minutes with DMEM and 1nM (þ)-naloxone or
1nM tubacin prior to the addition of the medium or 1mM
morphine. The cells were thereafter incubated for 2 hours
at 37C in a 5% CO2 atmosphere. The cells were then
washed with PBS and lysed in 200 mL of 1X Laemmli sample
buffer (Bio-Rad Laboratories, Inc., Hercules, CA, USA),
which contained 2-mercaptoethanol. Approximately
15e20 mg of protein was denatured by heating at 95C for 5
minutes, separated on 10% sodium dodecyl sulfate-
polyacrylamide gel, and transferred onto nitrocellulose
membranes (Bio-Rad Laboratories). The membranes were
then blocked by incubation for 1 hour at room temperature
in blocking buffer (5% nonfat milk in 50mM Tris-HCl, 154mM
NaCl, 0.05% Tween 20; pH 7.4), and then incubated over-
night at 4C with a 1:500 dilution in blocking buffer of goat
polyclonal antibodies against mouse ionized calcium bind-
ing adapter molecule-1 (Iba1, a microglia marker; Abcam,
Cambridge, UK) or mouse HDAC6 (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA) or mouse monoclonal
antibodies against mouse heat shock protein 90 (HSP90;
Abcam, Cambridge, UK) or mouse acetylated-a-tubulin or
a-tubulin (Sigma-Aldrich). The membrane was then incu-
bated for 1 hour at room temperature with a 1:2000 dilution
in blocking buffer of horseradish peroxidase-conjugated
donkey antigoat or antimouse immunoglobulin G (IgG)
antibodies (both from Chemicon International, CA).
Membrane-bound secondary antibodies were detected
using Chemiluminescenceplus reagent (Perkin Elmer Life and
Analytical Sciences, Waltham, MA, USA), and visualized
using a chemiluminescence imaging system (Syngene,
Cambridge, UK). For the final step, the blots were incu-
bated for 18 minutes at 56C in stripping buffer (62.6mM
Tris-HCl, pH6.7, 2% SDS, 100mM mercaptoethanol) and re-
probed with mouse monoclonal anti-b-actin antibody
(Sigma-Aldrich) and horseradish peroxidase-conjugated
goat antimouse IgG antibody (Chemicon) as the loading
control. The density of each band was measured using a
computer-assisted imaging analysis system (Gene Tools
Match software, Syngene, Cambridge, UK).Immunocytochemistry and image analysis
EOC13.31 cells at a density of 1  104 cells/cm2 were plated
on glass coverslips, washed three times with serum-free
DMEM, starved for 4 hours in the same medium, and then
incubated for 30 minutes with DMEM, 1nM (þ)-naloxone or
1nM tubacin. The medium or 1mM morphine was then added
and the cells were incubated for 2 hours at 37C in a 5% CO2
atmosphere. After fixation for 5 minutes at room tempera-
ture in 4% paraformaldehyde, the cells were incubated at 4C
overnight with goat polyclonal antibodies against mouse Iba1
(Abcam) diluted 1:100 in 2% normal goat serum in PBS with
0.01% Triton X-100. The cells were incubated for 1 hour at
room temperature with fluorescein isothiocyanate-labeled
donkey antigoat IgG antibodies (Santa Cruz Biotechnology,
Inc.) diluted in the same serum/buffer mixture. Images were
captured using an Olympus BX 50 fluorescence microscope
(Olympus, Optical, Tokyo, Japan) and a Delta Vision discon-
solation microscopic system operated by SPOT software(Diagnostic Instruments Inc., Sterling Heights, MI, USA).
Control cells without the primary antibody were included to
confirm the specificity of staining.
Statistical analysis
All experiments were performed at last three times and the
data are presented as the mean  the standard error of the
mean (SEM). Statistical analysis was performed using Sig-
maStat 3.0 software (SYSTAT Software Inc., San Jose, CA,
USA) for the Student t test after multiple comparisons of
one-way analysis of variance (ANOVA). A significant differ-
ence was defined as a p < 0.05.
Results
Ultralow dose (D)-naloxone inhibits morphine-
induced microglia activation and migration
To clarify the effect of (þ)-naloxone on microglia in
morphine tolerance, we used an in vitro culture system in
the following investigation. The primary microglia cell
culture is easily contaminated with fibroblasts and neurons,
which also express opioid receptors. Opioid receptors in
fibroblasts and neurons may also be affected by morphine.
The evaluation of (þ)-naloxone effects under this scenario
would consequently be complicated. Thus, we used the
microglia cell line EOC13.31 cell, which avoids fibroblast
and neuron contamination. EOC13.31 microglia cells were
incubated for 2 hours with different concentrations of
morphine (ranging from 10nM to 100mM). Migration
increased in a dose-dependent manner up to 1mM (with a
peak of 250.0  16.09% at 1mM; p Z 0.0006), and then
decreased, compared to the control group (Fig. 1A). Pre-
treatment for 30 minutes with different doses of
(þ)-naloxone prior to incubation with 1mM morphine for 2
hours significantly decreased morphine-induced microglia
migration from 250.0  16.09% with 1mM morphine alone to
110  5.93% after pretreatment with 1nM (þ)-naloxone
(p Z 0.0007; Fig. 1B). All subsequent experiments were
performed using 1mM morphine and 1nM naloxone.
Morphine induces Iba1 expression in microglia but
(D)-naloxone inhibits this effect
EOC13.31 cells exhibited a small, spherical shape just after
seeding in DMEM containing 10% FBS. Several minutes later,
the cells became firmly attached to the dish. Within 30e45
minutes, the cells spread and became flat and amoeboid-
like before shrinking. At 14e18 hours after seeding, the
cells became bipolar rod-like or globular in shape. At 24
hours after seeding, the cells were washed three times with
serum-free DMEM and starved for 4 hours in the same me-
dium. They were then preincubated with the medium or
1nM (þ)-naloxone for 30 minutes. The medium or morphine
was then added and the cells were incubated for 2 hours.
The microglia were then fixed for 5 minutes and stained
with antibodies against the microglia marker Iba1, which is
also an actin-binding protein. In the medium-treated cells
(Fig. 2A) and (þ)-naloxone-treated (Fig. 2B) cells, weak
Figure 1 Effect of ultralow dose (þ)-naloxone on morphine-induced EOC13.31 cell migration. (A) The dose-response effect of
morphine on EOC13.31 cell migration. The cells were incubated for 2 hours with serum-free medium alone (Con) or with medium
containing 10nM, 100nM, 1mM, 10mM, or 100mM morphine (Mo). A migration assay was then performed for 1 hour and the migrated
cells were counted. (B) The results after EOC13.31 cells were pretreated for 30 minutes with serum-free medium or the indicated
concentration of (þ)-naloxone (NLX). The serum or 1mM morphine (NLXþMo) was added for another 2 hours. A cell migration assay
was performed and the migrated cells were counted. (CeF) Images of stained migrated microglia at the bottom of the poly-
carbonate membrane from B. (G) The bar graph shows the quantitative data from Fig. 1CeF (*p < 0.01 and **p < 0.001, compared
to the Con group; ##p < 0.001, compared to the morphine-treated group). In bar graphs A, B, and G, the data are presented as the
mean  SEM (n Z 54). For all figures, SEM, standard error of the mean.
Ultralow dose of (þ)-naloxone and microglia 449immunostaining was present in resting microglia with a
small cell soma and long processes. By contrast, intense
immunoreactivity was present in morphine-treated micro-
glia with a large cell body and retracted processes (Fig. 2C).
Anti-Iba1 antibody-stained membrane ruffling (white ar-
rows) was present at the edge of the morphine-treated
microglia. Morphine-induced microglia activation and cell
membrane ruffling were abolished by 30 minutes pre-
treatment with (þ)-naloxone (Fig. 2D). Western blot anal-
ysis (Fig. 2E and F) of microglia protein extracts showed
that Iba1 expression was significantly increased
(2.46  0.15-fold) in the morphine-treated cells
(p Z 0.0008), compared to the serum-free control cells.
This effect was significantly decreased by ultralow dose
(þ)-naloxone pretreatment (1.38  0.07; p Z 0.0009,
compared to the serum-free control group; p Z 0.0004,
compared to the morphine-treated group).
Morphine reduces a-tubulin and acetylated a-
tubulin levels in microglia
To assess the role of a-tubulin in microglia chemotaxis
caused by morphine stimulation, we examined theexpression of a-tubulin and acetylated-a-tubulin by West-
ern blotting. As Fig. 3 shows, morphine treatment reduced
the density of the a-tubulin and acetylated-a-tubulin bands
from 1 to 0.66  0.06 (p Z 0.0006) and from 1 to
0.51  0.06 (pZ 0.0002), respectively, in the control cells.
Pretreatment with ultralow dose (þ)-naloxone significantly
inhibited these effects [relative expression of a-tubulin
0.94  0.10 (p Z 0.17) and acetylated-a-tubulin
0.89  0.15 (p Z 0.057)], compared to the completely
untreated controls. This suggests that morphine treatment
affects microtubule-mediated processes.
Morphine induces increased HDAC6 expression and
decreased HSP90 expression
Histone deacetylase 6 affects cell migration through regu-
lating cytoskeleton dynamics by a-tubulin acetylation
modulation.9 As Fig. 4A and B show, morphine treatment
increased the relative HDAC6 expression from 1 in the un-
treated control group to 2.0  0.12 (p Z 0.0001). This ef-
fect was significantly inhibited by pretreatment with
ultralow dose (þ)-naloxone (relative band density was
0.99  0.04, compared to the untreated control;
Figure 2 Morphine-induced membrane ruffling and ionized calcium binding adapter molecule-1 (Iba1) expression in EOC13.31
cells. EOC13.31 cells were washed three times with serum-free DMEM and starved for 4 hours in the same medium. They were then
incubated (A) for 2.5 hours with serum-free medium, or (B) for 30 minutes with serum-free medium. They were thereafter
incubated for 2 hours with medium containing morphine, (C) for 2.5 hours with medium containing ultralow dose (þ)-naloxone, or
(D) for 30 minutes with ultralow dose (þ)-naloxone and 2 hours with morphine. The cells were then immunostained for Iba1. The
white arrows indicate Iba1 in the ruffling membrane. (E) Western blot of Iba1 in a whole cell lysate of EOC13.31 cells (15 mg of
protein per lane). (F) Quantification of the data from (E) with the control value set as 1. b-Actin is the loading control. The data are
expressed as the mean  the SEM for three independent experiments (**p < 0.001, compared to the control group; ##p < 0.001,
compared to the morphine-treated group). Con Z control; DMEM Z Dulbecco’s modified Eagle’s medium; Mo Z morphine;
NLX Z (þ)-naloxone.
Figure 3 Ultralow dose (þ)-naloxone markedly inhibits the
morphine-induced decrease in a-tubulin and acetylated-a-
tubulin levels. EOC13.31 cells were treated as in Fig. 2. The
levels of a-tubulin and acetylated-a-tubulin were measured by
Western blotting. (A) Typical blot of a-tubulin and acetylated-
a-tubulin levels in the whole cell lysate (15 mg of protein per
lane). (B) Quantification of the data from (A) is expressed
relative to the control level, which is set as 1. b-Actin is the
loading control. The data are expressed as the mean  SEM for
three independent experiments. (**p < 0.001, compared to the
control group; ##p < 0.001, compared to the morphine-treated
group). Ace-a-tubulin Z acetylated-a-tubulin; Con Z control;
Mo Z morphine; NLX Z (þ)-naloxone.
Figure 4 Ultralow dose (þ)-naloxone blocks the morphine-
induced increase in histone deacetylase 6 (HDAC6) expression
in EOC13.31 cells. The cells were treated as in Fig. 2; the
HDAC6 levels were then measured by Western blotting. (A)
Typical Western blot of HDAC6 levels in the whole cell lysate
(25 mg of protein per lane). (B) Quantification of the data from
(A) is expressed relative to the control value of 1. b-Actin is the
loading control. The data are expressed as the mean  SEM for
three independent experiments. (**p < 0.001, compared to the
control group; ##p < 0.001, compared to the morphine-treated
group). Con Z control; Mo Z morphine; NLX Z (þ)-naloxone.
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and p Z 0.87, compared to the untreated control group).
As Fig. 5A and B show, morphine treatment furthermore
increased HDAC6 expression, but decreased the expression
of the downstream protein of HDAC6, HSP90 (90 kDa MW
band, relative band density 0.67  0.03; p Z 0.0001,
compared to the untreated control group), and induced
HSP90 cleavage (Fig. 5A). Ultralow dose (þ)-naloxone pre-
treatment significantly inhibited HSP90 cleavage and the
morphine-induced reduction of intact HSP90 levels
(0.96  0.04; p Z 0.0047, compared to the morphine-
treated group; p Z 0.16, compared to the control group).Figure 6 Tubacin blocks the morphine-induced decrease in
a-tubulin and acetylated-a-tubulin levels. The cells were
treated as in Fig. 2. The a-tubulin and acetylated a-tubulin
levels were measured by Western blotting. (A) Typical Western
blot of a-tubulin and acetylated-a-tubulin levels in a whole cell
lysate (15 mg of protein per lane). (B) Quantification of the data
from (A) is expressed relative to the control value of 1. b-Actin
is the loading control. The data are expressed as the
mean  SEM for three independent experiments. (**p < 0.001,
compared to the control group; #p < 0.05 ##p < 0.005,
compared to the morphine-treated group). Ace-a-
tubulin Z acetylated-a-tubulin; Con Z control;Morphine-induced a-tubulin deacetylation and
HSP90 cleavage in microglia is HDAC6-dependent
To confirm that the morphine-induced a-tubulin deacety-
lation and HSP90 cleavage were HDAC6-dependent, we
used the specific HDAC6 inhibitor tubacin (1nM) in the
following experiments. As Fig. 6A and B show, 30 minutes of
incubation with tubacin alone did not affect the levels of a-
tubulin or acetylated a-tubulin, whereas morphine treat-
ment decreased a-tubulin expression from 1 in the control
group to 0.53  0.04 (pZ 0.0004) and acetylated a-tubulin
levels decreased from 1 to 0.62  0.04 (p Z 0.0007). Pre-
treatment for 30 minutes with tubacin significantly inhibi-
ted the effect of morphine on a-tubulin (band density
relative to the control group 0.87  0.11, p Z 0.117; and
p Z 0.011, compared to the morphine-treated group).
Tubacin pretreatment completely suppressed the effect onFigure 5 Ultralow dose (þ)-naloxone blocks the morphine-
induced decrease in heat shock protein 90 (HSP90) expression
in EOC13.31 cells. The cells were treated as in Fig. 2. The
HSP90 levels were measured by Western blotting. (A) Typical
Western blot of HSP90 levels in a whole cell lysate (15 mg of
protein per lane). (B) Quantification of the data from (A) is
expressed relative to the control value of 1. b-Actin is the
loading control. The data are expressed as the mean  SEM for
three independent experiments (**p < 0.001, compared to the
control group; ##p < 0.005, compared to the morphine-treated
group). Con Z control; Mo Z morphine; NLX Z (þ)-naloxone.
Mo Z morphine; Tub Z tubacin.acetylated a-tubulin levels (1.04  0.06, p Z 0.35,
compared to the control group). As Fig. 7A and B show, the
morphine-induced a decrease in HSP90 expression
(0.64  0.05; p Z 0.0002, compared to the untreated
control group) was similarly significantly inhibited by
tubacin pretreatment (band intensity of 1.04  0.05;
pZ 0.0009, compared to the morphine-treated group; and
p Z 0.28, compared to the untreated control group).
Tubacin pretreatment also prevented morphine-induced
HSP90 fragmentation (Fig. 7A).Tubacin treatment reduces morphine-induced
microglia activation and migration
In an immunocytochemical study, morphine treatment
altered the morphology of the cells from ramified (Fig. 8A
and B) to an amoeboid shape with strong Iba1 immunore-
activity. This finding indicates that the microglia were
activated by morphine treatment (Fig. 8C), and that pre-
treatment for 30 minutes with tubacin significantly inhibi-
ted microglia activation (Fig. 8D). As Fig. 8E shows,
morphine treatment increased cell migration
(251.6  13.01%; p Z 0.0003, compared to the untreated
control group), and this effect was also significantly
inhibited by tubacin pretreatment (140.0  11.54%;
pZ 0.025, compared to the untreated control; pZ 0.003,
compared to the morphine-treated group).
Figure 7 Tubacin blocks the morphine-induced decrease in
heat shock protein 90 (HSP90) expression in EOC13.31 cells.
The cells were treated as in Fig. 2, except tubacin was used
instead of ultralow dose (þ)-naloxone. The HSP90 levels were
then measured by Western blotting. (A) Typical Western blot of
HSP90 levels in the whole cell lysate of the control (Con) cells,
tubacin (Tub)-treated cells, morphine (Mo)-treated cells, and
tubacin þ morphine (TubþMo)-treated cells (15 mg of protein
per lane). (B) Quantification of the data from (A) is expressed
relative to the control value of 1. b-Actin is the loading control.
The data are expressed as the mean  SEM for three inde-
pendent experiments (**p < 0.001, compared to the control
group; ##p < 0.001, compared to the morphine-treated group). Figure 8 Tubacin inhibits morphine-induced EOC13.31 acti-
vation and migration. EOC13.31 cells were treated as in Fig. 7,
and then were stained for ionized calcium binding adapter
molecule-1 (Iba1). Typical results for (A) control (Con) cells,
(B) tubacin (Tub)-treated cells, (C) morphine (Mo)-treated
cells, and (D) tubacinþmorphine (TubþMo)-treated cells. (E)
Quantification of microglia migration are expressed as the
mean  SEM (nZ 18) (*p < 0.05 and **p < 0.005, compared to
the control group; ##p < 0.005, compared to the morphine-
treated group).
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In the present study, we found that pretreatment with ul-
tralow dose (þ)-naloxone significantly inhibited morphine-
induced immune reactivity in EOC13.31 microglia cells. The
use of ultralow dose naloxone as an effective adjuvant with
opioids to inhibit morphine tolerance and dependence is
associated with changes in m-opioid receptor-G protein
coupling and the G protein subunit (b/g) signaling in
chronic morphine-tolerant rats.17 Our recent studies show
that ultralow dose ()-naloxone inhibits neuroinflammation
and preserves the antinociceptive effect of morphine in
neuropathic6 and morphine-tolerance13 animal models. At
that point, we did not know whether the antineuroin-
flammatory effect of ultralow dose ()-naloxone involved
an opioid receptor-mediated signaling pathway. However,
the present study proved that the effect was because of
mechanisms that do not involve opioid receptors. The study
found that ()-naloxone and (þ)-naloxone significantly
attenuated b-amyloid peptide-induced superoxide produc-
tion in microglia cells and that the anti-inflammatory effect
of naloxone may not be directly related to opioid re-
ceptors18 because (þ)-naloxone, which does not bind to
opioid receptors, had a marked anti-inflammatory effect.
Furthermore, (þ)-naloxone reduced cocaine-induced19 and
amphetamine-induced20 hyperactivity in mice. A recent
study also found that naloxone (100pM) inhibited opioid-
dependent microglia migration by downregulating the ion-
otropic purinergic receptor P2X4.
21 These results altogetherconfirm that an ultralow dose of (þ)-naloxone inhibited
microglia activation through opioid receptor-independent
mechanisms.
We previously found that chronic in vivo morphine
infusion produces marked microglia activation.22 However,
we do not know whether this effect on the microglia is a
direct effect of the morphine or an indirect effect of
stimulating neurons or astrocytes. In a previous study,21
microglia cell cultures have been used to determine the
modulatory effect of morphine on microglia migration as
the first step in exploring the role of immunocompetent
cells in the actions of opioid. The study showed that ul-
tralow dose naloxone inhibited opioid-dependent microglia
migration by modulating the ionotropic purinergic receptor,
P2X4. In the present study, we provided evidence that
morphine changes the morphology of cultured microglia
from a ramified structure to an amoeboid shape and in-
duces cell chemotaxis and membrane ruffling.
Membrane ruffling exists at the front edge of a migrating
cell and may be a driving force in chemotaxis.23 Our results
Ultralow dose of (þ)-naloxone and microglia 453showed that morphine directly enhanced microglia
chemotaxis and membrane ruffling and that these actions
were accompanied by an increase in Iba1 protein expres-
sion in the microglia, especially in the ruffling membrane.
Pretreatment with 1nM (þ)-naloxone significantly inhibited
microglia migration, activation, and reduced Iba1 expres-
sion in microglia. On the basis of these results, we suggest
that Iba1 is involved in microglia migration and that ultra-
low dose (þ)-naloxone may regulate actin cytoskeleton
dynamics.
Activation of microglia is accompanied by a change in
cell morphology and enhanced adhesion and migration.
These processes are dependent on the rate of assembly/
disassembly of the cytoskeleton. There are three main
types of cytoskeletal filament: microfilaments, intermedi-
ate filaments, and microtubules.24 Microtubules are major
organizers of the cell and are vitally involved in activities
such as mitosis, adhesion, migration, and ordered vesicle
transport powered by motor proteins.25 In the cell, there is
a dynamic equilibrium between microtubule polymeriza-
tion and depolymerization,26,27 which relies on post-
translational modifications such as a-tubulin detyrosina-
tion and acetylation.28 Acetylation occurs on lysine 40 of a-
tubulin, which is present in stable microtubules in most cell
types.29 A decrease in a-tubulin acetylation reduces
microtubule stability.30 One study31 found that microtubule
stabilization is actively involved in axon formation in rat
primary hippocampal neurons. These results imply that
stabilization of a-tubulin and microtubules are involved in
maintaining several crucial cellular processes such as
morphogenesis, compartmentalization, and organelle
movement. In our present study, we found that morphine
treatment decreased a-tubulin and acetylated a-tubulin
levels in EOC13.31 cells. These effects were associated
with microglia activation and migration, and demonstrate a
direct relationship between a-tubulin stabilization and cell
function. Marie-Claire et al32 demonstrated that chronic
morphine treatment significantly decreases the mRNA and
protein levels of a-tubulin and the microtubule stabilization
protein tau in the rat striatum. Based on these results, we
suggest that chronic morphine administration modifies the
gene and protein expression pattern of a-tubulin and other
microtubule-associated components that may directly
affect microtubule stabilization. In the present study,
pretreatment with ultralow dose (þ)-naloxone significantly
inhibited the morphine-induced reduction in a-tubulin and
acetylated a-tubulin levels. We therefore suggest that ul-
tralow dose (þ)-naloxone can alter microtubule dynamics
and that the underlying mechanisms may be associated
with inhibiting HDAC6 expression.
A previous study33 has shown that HDAC6 acts as an a-
tubulin deacetylase, which affects microtubule-mediated
processes through deacetylase-dependent and deacetyla-
seeindependent mechanisms. Histone deacetylase 6 is
localized in the motile and protrusive structures of polar-
ized cells such as the leading edge and membrane ruffles.34
In activated T cells, increased acetylated a-tubulin levels
exist around the microtubule organizing center and are
partially colocalized with HDAC6.35 Zhang et al36 also report
that, in NIH 3T3 cells, HDAC6 directly deacetylates cor-
tactin and thus favors its binding to F-actin; they also
suggest that it modulates motility through cortactindeacetylation. Our results similarly showed that morphine
treatment increased HDAC6 expression in microglia and this
increase was accompanied by decreased tubulin acetyla-
tion and increased microglia activity. Thus, HDAC6 deace-
tylase activity seems important in microtubule
configuration and cell migration. In the present study, we
provided evidence that chronic morphine treatment of
microglia induced HDAC6 overexpression and thus pro-
moted a-tubulin deacetylation and increased microglia
motility. We also found that ultralow dose (þ)-naloxone or
tubacin inhibited the morphine-induced increase in HDAC6
expression. Based on these results, we suggest that the
inhibitory effect of ultralow dose (þ)-naloxone on
morphine-evoked microglia activation and chemotaxis is
produced via the inhibition of HDAC6 expression.
Modulation of microtubule dynamics provides a link to
important HDAC6 functions. For example, HDAC6 regulation
of protein degradation is important for maintaining cellular
homeostasis in the CNS.37 A recent study suggests that
HDAC6 may regulate the autophagy-mediated and ubiquitin
proteasome system-dependent degradation pathway.38 In
addition, HDAC6 regulates the activity of the chaperone
protein HSP90, and provide a further mechanistic insight
into its role in protein degradation.39 In the present study,
we found that increased HDAC6 expression induced HSP90
cleavage in morphine-treated microglia and that the inhi-
bition of HDAC6 significantly inhibited HSP90 cleavage. This
suggests that morphine induced HSP90 cleavage by stimu-
lating HDAC6 expression. It will be interesting to explore
how HDAC6 modulates HSP90 fragmentation and how ul-
tralow dose (þ)-naloxone prevents this effect. In a
nephrotoxin-induced injury renal cell model,40 the authors
found that HSP90 directly interacts with tubulin, protects it
against thermal denaturation, and maintains it in a state
compatible with microtubule polymerization. These au-
thors also demonstrated that HSP90 does not cause disag-
gregation of aggregated tubulin; it instead binds to early
unfolding intermediates to prevent their aggregation. The
HSP90 inhibitor geldanamycin counteracts the protective
effect of HSP90 on tubulin. The result suggests that HSP90
may have a role in the regulation of microtubule cytoskel-
eton polymerization/depolymerization. Heat shock protein
90 is a stress response protein that responds immediately to
a variety of stresses on the cells and may have an important
role in cell defense mechanisms.41 In our present study, we
found that morphine treatment downregulated HSP90
expression and induced HSP90 cleavage in microglia cells,
which was accompanied by a-tubulin downregulation. We
therefore suggest that morphine treatment may lead to a
stress situation in microglia, induce HSP90 fragmentation,
and thus decrease its ability to protect a-tubulin. In our
present study, pretreatment with ultralow dose
(þ)-naloxone significantly inhibited this stress response.
In summary, the present study revealed a novel inter-
action between morphine and the HDAC6/HSP90/a-tubulin
signaling pathway that mediates microglia migration. This
study is an integral first step in assessing the role of
microglia activation in morphine tolerance, hyperalgesia,
and other adverse effects. The functions of microglia may
prove to be valuable targets for the development of new
therapy aimed at attenuating morphine-induced adverse
effects. This study provides new evidence that ultralow
454 R.-Y. Tsai et al.dose (þ)-naloxone may have potential as an analgesic
adjuvant in clinical pain management, particularly for pa-
tients who need long-term morphine treatment and
morphine-tolerant patients who require better pain relief.Acknowledgments
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